144 related articles for article (PubMed ID: 38414346)
21. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.
Ghannoum M; Long L; Kunze G; Sarkany M; Osman-Ponchet H
Mycoses; 2019 Jun; 62(6):494-501. PubMed ID: 30667544
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of antifungal agents against fungal spores: An in vitro study using microplate laser nephelometry and an artificially infected 3D skin model.
Fink S; Burmester A; Hipler UC; Neumeister C; Götz MR; Wiegand C
Microbiologyopen; 2022 Feb; 11(1):e1257. PubMed ID: 35212482
[TBL] [Abstract][Full Text] [Related]
23. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
[TBL] [Abstract][Full Text] [Related]
24. Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.
Tabara K; Szewczyk AE; Bienias W; Wojciechowska A; Pastuszka M; Oszukowska M; Kaszuba A
Postepy Dermatol Alergol; 2015 Feb; 32(1):40-5. PubMed ID: 25821426
[TBL] [Abstract][Full Text] [Related]
25. Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.
Wiederhold NP; Fothergill AW; McCarthy DI; Tavakkol A
Antimicrob Agents Chemother; 2014 Jun; 58(6):3553-5. PubMed ID: 24709260
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection.
Schaller M; Borelli C; Berger U; Walker B; Schmidt S; Weindl G; Jäckel A
Med Mycol; 2009 Nov; 47(7):753-8. PubMed ID: 19888808
[TBL] [Abstract][Full Text] [Related]
27. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
[TBL] [Abstract][Full Text] [Related]
28. Topical and device-based treatments for fungal infections of the toenails.
Foley K; Gupta AK; Versteeg S; Mays R; Villanueva E; John D
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012093. PubMed ID: 31978269
[TBL] [Abstract][Full Text] [Related]
29. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays.
Sigurgeirsson B; Ghannoum MA; Osman-Ponchet H; Kerrouche N; Sidou F
Mycoses; 2016 May; 59(5):319-26. PubMed ID: 26867498
[TBL] [Abstract][Full Text] [Related]
30. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis.
Baran R
Br J Dermatol; 2001 Oct; 145 Suppl 60():15-9. PubMed ID: 11777260
[TBL] [Abstract][Full Text] [Related]
31. Onychomycosis in children: a brief overview with treatment strategies.
Gupta AK; Skinner AR
Pediatr Dermatol; 2004; 21(1):74-9. PubMed ID: 14871333
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.
Shimamura T; Kubota N; Nagasaka S; Suzuki T; Mukai H; Shibuya K
Antimicrob Agents Chemother; 2011 Jul; 55(7):3150-5. PubMed ID: 21555762
[TBL] [Abstract][Full Text] [Related]
33. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis.
Carrillo-Muñoz AJ; Giusiano G; Cárdenes D; Hernández-Molina JM; Eraso E; Quindós G; Guardia C; del Valle O; Tur-Tur C; Guarro J
Int J Antimicrob Agents; 2008 Jun; 31(6):540-3. PubMed ID: 18367383
[TBL] [Abstract][Full Text] [Related]
34. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
Avner S; Nir N; Henri T
J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
Tabata Y; Takei-Masuda N; Kubota N; Takahata S; Ohyama M; Kaneda K; Iida M; Maebashi K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1035-9. PubMed ID: 26643333
[TBL] [Abstract][Full Text] [Related]
36. Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis.
Seebacher C
Mycoses; 2003 Dec; 46(11-12):506-10. PubMed ID: 14641625
[TBL] [Abstract][Full Text] [Related]
37. The use of topical therapies to treat onychomycosis.
Gupta AK; Ryder JE; Baran R
Dermatol Clin; 2003 Jul; 21(3):481-9. PubMed ID: 12956200
[TBL] [Abstract][Full Text] [Related]
38. Onychomycosis: Diagnosis and management.
Singal A; Khanna D
Indian J Dermatol Venereol Leprol; 2011; 77(6):659-72. PubMed ID: 22016272
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
Täuber A; Müller-Goymann CC
Mol Pharm; 2014 Jul; 11(7):1991-6. PubMed ID: 24490976
[TBL] [Abstract][Full Text] [Related]
40. Penetration Profile of Terbinafine Compared to Amorolfine in Mycotic Human Toenails Quantified by Matrix-Assisted Laser Desorption Ionization-Fourier Transform Ion Cyclotron Resonance Imaging.
Joly-Tonetti N; Legouffe R; Tomezyk A; Gumez C; Gaudin M; Bonnel D; Schaller M
Infect Dis Ther; 2024 Jun; 13(6):1281-1290. PubMed ID: 38713301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
